Clinical implications of a molecular genetic classification of monogenic β-cell diabetes
The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Monogenic diabetes resulting from mutations that primarily reduce beta-cell function accounts for 1-2% of diabetes cases, although it is often misdiagnosed as either type 1 or type 2 diabetes. Knowledge of the genetic etiology of diabetes enables more-appropriate treatment, better prediction of disease progression, screening of family members and genetic counseling. We propose that the old clinical classifications of maturity-onset diabetes of the young and neonatal diabetes are obsolete and that specific genetic etiologies should be sought in four broad clinical situations because of their specific treatment implications. Firstly, diabetes diagnosed before 6 months of age frequently results from mutation of genes that encode Kir6.2 (ATP-sensitive inward rectifier potassium channel) or sulfonylurea receptor 1 subunits of an ATP-sensitive potassium channel, and improved glycemic control can be achieved by treatment with high-dose sulfonylureas rather than insulin. Secondly, patients with stable, mild fasting hyperglycemia detected particularly when they are young could have a glucokinase mutation and might not require specific treatment. Thirdly, individuals with familial, young-onset diabetes that does not fit with either type 1 or type 2 diabetes might have mutations in the transcription factors HNF-1alpha (hepatocyte nuclear factor 1-alpha) or HNF-4alpha, and can be treated with low-dose sulfonylureas. Finally, extrapancreatic features, such as renal disease (caused by muta…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, an exception is the mutational analyses established for classification of diabetes in the neonate (381-384) as well as in young individuals with a dominant family history of diabetes, often referred to as maturityonset diabetes of the young (MODY) (384,385) (Table 8).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [383]
In the citing paper
“Infants with neonatal diabetes due to a mutation in the KCNJ11 (potassium inwardly-rectifying channel, subfamily J, member 11; also known as KIR6.2) gene may be treated with sulfonylurea rather than with insulin (258,259).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [258]
In the citing paper
“Genetic markers are currently of limited clinical value in evaluating and managing patients with diabetes; however, mutational analysis is rapidly emerging for classifying diabetes in the neonate (258-260) and in young patients with a dominant family history of diabetes, often referred to as “maturityonset diabetes of the young” (MODY) (261).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [258]
Citations
Cites
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F., & Ochs, H. D. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,402
Goto, Y.-I., Nonaka, I., & Horai, S. (1990) · Nature · doi:10.1038/348651a0 · Cited by 2,070
Wildin, R. S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J.-L., Buist, N., Levy-Lahad, E., Mazzella, M., Goulet, O., Perroni, L., et al. (2001) · Nature Genetics · doi:10.1038/83707 · Cited by 1,922
Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, A. S., Howard, N., Srinivasan, S., Silva, J. M. C. L., Molnes, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032922 · Cited by 1,137
Self-citationSwitching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988
Self-citationChatila, T. A., Blaeser, F., Ho, N., Lederman, H. M., Voulgaropoulos, C., Helms, C., & Bowcock, A. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11679 · Cited by 940
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 1×
“Currently, insulin remains the most common treatment during pregnancy for this patient group, but further studies are required to validate the safety and efficacy of sulfonylureas such as glibenclamide (also known as glyburide) that have least permeability through the placenta and have been used in gestational diabetes”
BackgroundEarly-onset type-ll diabetes mellitus (MODY4) linked to IPF1
Staffers, D. A., Ferrer, J., Clarke, W. L., & Habener, J. F. (1997) · Nature Genetics · doi:10.1038/ng1097-138 · Cited by 882
Delépine, M., Nicolino, M., Barrett, T., Golamaully, M., Mark Lathrop, G., & Julier, C. (2000) · Nature Genetics · doi:10.1038/78085 · Cited by 813
Froguel, P., Zouali, H., Vionnet, N., Velho, G., Vaxillaire, M., Sun, F., Lesage, S., Stoffel, M., Takeda, J., Passa, P., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303113281005 · Cited by 735 · cited 1×
“Most of those without diabetes have impaired fasting glucose levels”
Background
Research works printed but not linked: 1
- Pearson E et al. (2003) HDL-cholesterol: differentiating between HNF-1α MODY and type 2 diabetes [abstract]. Diabet Med 20 (Suppl 2): S1–S33
Cited by
Items 101–200 of 500
Evaluation of a target region capture sequencing platform using monogenic diabetes as a study-model
Gao, R., Liu, Y., Gjesing, A. P., Hollensted, M., Wan, X., He, S., Pedersen, O., Yi, X., Wang, J., & Hansen, T. (2014) · BMC Genetics · doi:10.1186/1471-2156-15-13 · Cited by 58
“Background Since 1992, several genetic subtypes of monogenetic diabetes have been described in which gene mutations result in diabetes, primarily by causing beta-cell dysfunction [1].”
InfluentialMohamadi, A., Clark, L. M., Lipkin, P. H., Mahone, E. M., Wodka, E. L., & Plotnick, L. P. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00548.x · Cited by 58
Doss, C. G. P., Chakraborty, C., Haneef, S. S., Nagasundaram, N., Chen, L., & Zhu, H. (2014) · Theranostics · doi:10.7150/thno.7473 · Cited by 60
“Most activating mutations are located within the allosteric activator site where GKAs bind, whereas inactivating mutations that lead to hyperglycaemia are located throughout the protein [19,24,25].”
BackgroundConcise Review: Human Pluripotent Stem Cells for the Modeling of Pancreatic β-Cell Pathology
Balboa, D., Saarimäki‐Vire, J., & Otonkoski, T. (2018) · Stem Cells · doi:10.1002/stem.2913 · Cited by 69
Benitez, C. M., Qu, K., Sugiyama, T., Pauerstein, P. T., Liu, Y., Tsai, J., Gu, X., Ghodasara, A., Arda, H. E., Zhang, J., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004645 · Cited by 56
“To obtain the GSEA enrichment score of diabetes risk factor genes, we compiled a total of 72 risk factor genes from [42] and [88].”
MethodSearching for maturity-onset diabetes of the young (MODY): when and what for?
Timsit, J., Saint-Martin, C., Dubois-Laforgue, D., & Bellanné-Chantelot, C. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.12.005 · Cited by 55
Radha, V., Ek, J., Anuradha, S., Hansen, T. F., Pedersen, O. B., & Mohan, V. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2371 · Cited by 55
Østoft, S. H., Bagger, J. I., Hansen, T., Pedersen, O., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2014) · Diabetes · doi:10.2337/db13-1878 · Cited by 55
Warncke, K., Kummer, S., Raile, K., Grulich-Henn, J., Woelfle, J., Steichen, E., Prinz, N., & Holl, R. W. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01696 · Cited by 52
Imaging of β-Cell Mass and Insulitis in Insulin-Dependent (Type 1) Diabetes Mellitus
Gialleonardo, V. D., de Vries, E. F. J., Girolamo, M. D., Quintero, A., Dierckx, R., & Signore, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1041 · Cited by 63
Clinical Heterogeneity in Monogenic Diabetes Caused by Mutations in the Glucokinase Gene (GCK-MODY)
Cuesta-Muñoz, A. L., Tuomilehto, J., Cobo‐Vuilleumier, N., Rajala, H. L. M., Odili, S., Stride, A., Buettger, C. W., Otonkoski, T., Froguel, P., Grimsby, J. S., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0681 · Cited by 59
“Cuesta-Muñoz, MD, PHD*((1)), Tiinamaija Tuomi, MD, PHD*((2)), Nadia CoboVuilleumier, MSC((1)), Hanna Koskela PHD((2)), Stella Odili, BA, Amanda Stride, MRCP((4)), Carol Buettger, BA((3)), Timo Otonkoski, MD((5)), Philippe Froguel, MD, PHD ((6)), Joseph Grimsby, PHD((7)), Maria Garcia-Gimeno, PHD((8)) and Franz M.”
BackgroundDiabetes mellitus due to the toxic misfolding of proinsulin variants
Weiss, M. A. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.04.044 · Cited by 55
Juszczak, A., Štambuk, T., Vučković, F., Bennett, A. J., Shah, N., Medvidović, E. P., Groves, C. J., Šekerija, M., Chandler, K. A., Burrows, C., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0422 · Cited by 52
“endogenous insulin production, absence of pancreatic autoimmunity, and consecutive generations of diabetes (2,3).”
BackgroundAllen, H. L., Johansson, S., Ellard, S., Shields, B. M., Hertel, J. K., Ræder, H., Colclough, K., Molven, A., Frayling, T. M., Njølstad, P. R., et al. (2009) · Diabetes · doi:10.2337/db09-0555 · Cited by 55
“There are at least eight genetic subgroups of MODY (1,2), with most patients having mutations in transcription factor genes.”
BackgroundSelf-citationAn Activating Mutation in STAT3 Results in Neonatal Diabetes Through Reduced Insulin Synthesis
Velayos, T., Martínez, R., Alonso, M., García‐Etxebarria, K., Aguayo, A., Camarero, C., Urrutia, I., de la Piscina, I. M., Barrio, R., Santín, I., et al. (2017) · Diabetes · doi:10.2337/db16-0867 · Cited by 48
“Genetic studies have allowed the identification of several causal point mutations and chromosomal aberrations in ;20 genes implicated in b-cell development, glucose sensing and metabolism, membrane depolarization, and apoptosis (2).”
BackgroundMethodInfluentialEmerging Type 2 Diabetes in Young Adults
Song, S. H. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_7 · Cited by 44
Andersson, C., Kolmodin, M., Ivarsson, S.-A., Carlsson, A., Forsander, G., Lindblad, B., Ludvigsson, J., Kockum, I., Marcus, C., Samuelsson, U., et al. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12093 · Cited by 44
“Analysis of MODY 1–3 were performed in all islet autoantibody negative patients in the BDD study by the Diabetes Research Department and the Centre for Molecular Genetics at the Peninsula Medical School and Royal Devon and Exeter Hospital, Exeter, UK (39).”
BackgroundGreeley, S. A. W., Tucker, S. E., Worrell, H. I., Skowron, K. B., Bell, G. I., & Philipson, L. H. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328334f158 · Cited by 45
Challenges in diagnosis and management of diabetes in the young
Unnikrishnan, R., Shah, V. N., & Mohan, V. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0036-6 · Cited by 47
“plasma glucose levels that rise minimally following a glucose load [34].”
BackgroundAlthari, S., Najmi, L. A., Bennett, A. J., Aukrust, I., Rundle, J. K., Colclough, K., Molnes, J., Kaci, A., Nawaz, S., van der Lugt, T., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.08.016 · Cited by 40
“Until relatively recently, the consensus has been that heterozygous highly penetrant loss-of-function alleles inHNF1A give rise to a clinically distinct diabetes subtype, characterized by an early age of onset (typically < 25 years), dominant inheritance, sensitivity to sulphonylureas, and non-obesity, and termed HNF1…”
BackgroundSelf-citationPermanent neonatal diabetes: different aetiology in Arabs compared to Europeans
Habeb, A. M., Flanagan, S. E., Deeb, A., Al-Alwan, I., Alawneh, H., Balafrej, A. A. L., Mutair, A., Hattersley, A. T., Hussain, K., & Ellard, S. (2012) · Archives of Disease in Childhood · doi:10.1136/archdischild-2012-301744 · Cited by 42
Self-citationThe use of precision diagnostics for monogenic diabetes: a systematic review and expert opinion
Murphy, R., Colclough, K., Pollin, T. I., Iklé, J. M., Svalastoga, P., Maloney, K. A., Saint‐Martin, C., Molnes, J., PMDI, A., Tobias, D. K., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00369-8 · Cited by 58
“Median score for the discovery group was 8 (0-24), with a higher median score of 12 (6-22) in HNF1B.”
BackgroundSelf-citationThe role of pancreatic imaging in monogenic diabetes mellitus
Haldorsen, I. S., Ræder, H., Vesterhus, M. N., Molven, A., & Njølstad, P. R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.197 · Cited by 43
“are often misdiagnosed as either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM)”
BackgroundAğladıoğlu, S. Y., Aycan, Z., Çetinkaya, S. Ç., Baş, V. N., Önder, A., Kendırcı, H. N. P., Doğan, H., & Ceylaner, S. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2015-0039 · Cited by 43
“Therefore, correct genetic diagnosis is important for lifelong treatment and patient prognosis [3].”
Molecular genetic testing of patients with monogenic diabetes and hyperinsulinism
Bennett, J. T., Vasta, V., Zhang, M., Narayanan, J., Gerrits, P., & Hahn, S. H. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.12.304 · Cited by 41
“Misdiagnosis with type 2 diabetes is possible as well [2,5].”
Pal, A., Farmer, A. A., Dudley, C., Selwood, M. P., Barrow, B. A., Klyne, R., Grew, J., McCarthy, M. I., Gloyn, A. L., & Owen, K. R. (2009) · Diabetes Care · doi:10.2337/dc09-1246 · Cited by 39
“have distinct phenotypes (1,3), differen-”
Epigenetics: New Concepts of Old Phenomena in Vascular Physiology
Krause, B., Sobrevia, L., & Casanello, P. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109789043883 · Cited by 40
Huerta‐Chagoya, A., Schroeder, P. H., Mandla, R., Li, J., Morris, L., Vora, M., Alkanaq, A. N., Nagy, D., Szczerbiński, Ł., Madsen, J. G. S., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01947-9 · Cited by 51
“Many monogenic diabetes subtypes are well suited for precision medicine interventions 11 , but the Article https://doi.org/10.1038/s41588-024-01947-9 the effective sample size of our meta-analysis being smaller (172,321 in our study versus 765,591 in ref.”
InfluentialModeling different types of diabetes using human pluripotent stem cells
Abdelalim, E. M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03710-9 · Cited by 38
Zung, A., Petek, E., Ben‐Zeev, B., Schwarzbraun, T., & Josefsberg, S. B. Y. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33829 · Cited by 37
“, 2001], as diabetes-associated complications are rare in this type of diabetes [Fajans et al., 2001; Murphy et al., 2008].”
BackgroundInfluentialIndividualized Therapy for Type 2 Diabetes: Clinical Implications of Pharmacogenetic Data
Mannino, G. C., & Sesti, G. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-012-0002-7 · Cited by 45
“Interest in ABCC8 and KCNJ11 as candidate pharmacogenomic genes in T2DM has evolved from clinical experience: gain-of-function mutations generate a constantly open KATP channel state, induce membrane hyperpolarization, and impair insulin release [117] in transient and permanent neonatal diabetes mellitus [118, 119]; l…”
BackgroundHow Heterogeneity in Glucokinase and Gap-Junction Coupling Determines the Islet [Ca2+] Response
Dwulet, J. M., Ludin, N. W. F., Piscopio, R. A., Schleicher, W. E., Moua, O., Westacott, M. J., & Benninger, R. K. P. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2019.10.037 · Cited by 41
“Many forms of monogenic diabetes arise from mutations to genes that encode components regulating insulin secretion (66).”
BackgroundYahaya, T., & Ufuoma, S. B. (2020) · Oman Medical Journal · doi:10.5001/omj.2020.44 · Cited by 45
Galán, M., García-Herrero, C.-M., Azriel, S., Gargallo, M., Durán, M., Gorgojo, J.-J., Andía, V.-M., & Navas, M.-A. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00097 · Cited by 37
“| M O L M E D 1 7 ( 3 - 4 ) 2 5 6 - 2 6 5 , M A R C H - A P R I L 2 0 1 1 INTRODUCTION Heterozygous mutations in the gene encoding hepatocyte nuclear factor 1-α (HNF-1α) are the cause of familial young-onset diabetes, also known as maturity-onset diabetes of the young (MODY)-3 (1).”
BackgroundMethodTwo Cases of Diabetic Ketoacidosis in HNF1A-MODY Linked to Severe Dehydration
Průhová, Š., Dušátková, P., Neumann, D., Hollay, E., Cinek, O., Lebl, J., & Šumník, Z. (2013) · Diabetes Care · doi:10.2337/dc13-0058 · Cited by 38
“patient education and for individual assessment of the indication criteria for genetic testing because, although the molecular genetic diagnosis of MODY diabetes has direct implications for patient treatment (4), most cases ofMODY remain misclassified (5).”
BackgroundPDX1 ‐ MODY and dorsal pancreatic agenesis: New phenotype of a rare disease
Caetano, L. A., de Santana, L. S., Costa‐Riquetto, A. D., Lerário, A. M., Nery, M., Nogueira, G. F., Ortega, C. D., Rocha, M. D. S., Jorge, A. A. L., & Teles, M. G. (2017) · Clinical Genetics · doi:10.1111/cge.13044 · Cited by 36
“The proband was selected for molecular analysis of MODY since he met the clinical criteria (age of diabetes onset < 35 years, family history of diabetes, absence of obesity, negative pancreatic antibodies and detectable C-peptide levels 3 to 5 years after diabetes diagnosis).(7) We designed a customized next-generatio…”
MethodA−β− Subtype of Ketosis-Prone Diabetes Is Not Predominantly a Monogenic Diabetic Syndrome
Haaland, W. C., Scaduto, D. I., Maldonado, M. R., Mansouri, D. L., Nalini, R., Iyer, D., Patel, S. G., Guthikonda, A., Hampe, C. S., Balasubramanyam, A., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1529 · Cited by 36
“(9) proposed a classification scheme for monogenic diabetes resulting from mutations that cause -cell dysfunction, a scheme that is based on specific genetic diagnoses and points to specific therapeutic interventions.”
BackgroundGlotov, O. S., Serebryakova, E. A., Turkunova, M. E., Efimova, O. A., Glotov, A. S., Barbitoff, Y. A., Nasykhova, Y. A., Predeus, A. V., Polev, D. E., Fedyakov, M. А., et al. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10751 · Cited by 37
“…variants may develop diabetes by the age of 35 years or even by the age of 55 years, although most of them have diabetes before 25 years of age (67). in the study by lópez-Garrido et al (68), the co-inheritance of GCK and HNF1A genetic variants was reported in two patients and was associated…”
Alvelos, M. I., Rodrigues, M., Lobo, L., Medeira, A., Sousa, A. B., Simão, C., & Lemos, M. C. (2015) · Medicine · doi:10.1097/md.0000000000000469 · Cited by 34
“In addition, some individuals present urogenital abnormalities that include bicornuate uterus, bilateral agenesis of vas deferens, large epididymal cysts, and asthenospermia.(6) HNF1B is located on chromosome 17q12 and comprises nine coding exons.”
BackgroundAberrant development of pancreatic beta cells derived from human iPSCs with FOXA2 deficiency
Elsayed, A. K., Younis, I., Ali, G., Hussain, K., & Abdelalim, E. M. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03390-8 · Cited by 35
Precision Diabetes Is Slowly Becoming a Reality
Mohan, V., & Radha, V. (2019) · Medical Principles and Practice · doi:10.1159/000497241 · Cited by 36
Mitochondrial Diabetes in Children: Seek and You Will Find It
Mazzaccara, C., Iafusco, D., Liguori, R., Ferrigno, M., Galderisi, A., Vitale, D., Simonelli, F., Landolfo, P., Prisco, F., Masullo, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034956 · Cited by 32
Practical Aspects of Monogenic Diabetes: A Clinical Point of View
Lachance, C.-H. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.11.004 · Cited by 37
Monogenic Diabetes: A Diagnostic Algorithm for Clinicians
Carroll, R. W., & Murphy, R. (2013) · Genes · doi:10.3390/genes4040522 · Cited by 34
“Extrapancreatic roles of these transcription factors reflect their specific phenotypes which serve as useful diagnostic clues: HNF1A is also expressed in the renal tubule and HNF1A mutations result in impaired tubular glucose reabsorption, thus manifesting glycosuria at blood glucose levels <10 mmol/L (low renal gluco…”
BackgroundInfluentialSelf-citationValentínová, L., Beer, N. L., Staník, J., Tribble, N. D., van de Bunt, M., Hučková, M., Barrett, A., Klimeś, I., Gašperíková, D., & Gloyn, A. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034541 · Cited by 32
“Micro and macrovascular complications are rare and patients can usually be treated by diet modification alone [3].”
BackgroundKooptiwut, S., Plengvidhya, N., Chukijrungroat, T., Sujjitjoon, J., Semprasert, N., Furuta, H., & Yenchitsomanus, P. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.025 · Cited by 31
New insights from monogenic diabetes for “common” type 2 diabetes
Tallapragada, D. S. P., Bhaskar, S., & Chandak, G. R. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00251 · Cited by 35
“…intact and vascular complications are not commonly observed in these patients and hence they do not require any pharmacological intervention and dietary intervention is usually sufficient to maintain stable glycosylated hemoglobin levels (HbA1c) levels (Stride et al., 2002; Murphy et al., 2008).”
BackgroundKawakita, R., Hosokawa, Y., Fujimaru, R., Tamagawa, N., Urakami, T., Takasawa, K., Moriya, K., Mizuno, H., Maruo, Y., Takuwa, M., et al. (2014) · Diabetic Medicine · doi:10.1111/dme.12487 · Cited by 30
Identifying monogenic diabetes in a pediatric cohort with presumed type 1 diabetes
Gandica, R., Chung, W. K., Deng, L., Goland, R., & GALLAGHER, M. P. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12150 · Cited by 31
Lupus: How much “complexity” is really (just) genetic heterogeneity?
Crow, Y. J. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30603 · Cited by 31
García-Herrero, C.-M., Rubio‐Cabezas, O., Azriel, S., Gutierrez‐Nogués, Á., Aragonés, Á., Vincent, O., Campos‐Barros, Á., Argente, J., & Navas, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030518 · Cited by 29
“In contrast, homozygous inactivating mutations cause complete GK deficiency and permanent neonatal diabetes mellitus (PNDM), whereas heterozygous inactivating mutations cause familial, mild fasting hyperglycaemia also known as maturity-onset diabetes of the young type 2 (MODY2; [10] [11]).”
BackgroundMethodGreeley, S. A. W., Naylor, R. N., Cook, L. S., Tucker, S. E., Lipton, R. B., & Philipson, L. H. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500409 · Cited by 28
Hidden MODY—Looking for a Needle in a Haystack
Urbanová, J., Brunerová, L., & Brož, J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00355 · Cited by 27
Alkandari, H., Al‐Abdulrazzaq, D., Davidsson, L., Nizam, R., Jacob, S. P., Melhem, M., John, S. E., & Al‐Mulla, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-95552-z · Cited by 30
dUTPase (DUT) Is Mutated in a Novel Monogenic Syndrome With Diabetes and Bone Marrow Failure
dos Santos, R. S., Daures, M., Philippi, A., Romero, S., Marselli, L., Marchetti, P., Senée, V., Bacq‐Daian, D., Besse, C., Baz, B., et al. (2017) · Diabetes · doi:10.2337/db16-0839 · Cited by 30
“These mutations have been identified in the context of familial or atypical clinical presentations, which may affect various organs (1,2).”
BackgroundThurner, M., Shenhav, L., Wesolowska‐Andersen, A., Bennett, A. J., Barrett, A., Gloyn, A. L., McCarthy, M. I., Beer, N. L., & Efrat, S. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.09.020 · Cited by 27
“These include diabetes-relevant terms such as maturity-onset diabetes of the young (MODY), a form of monogenic diabetes caused mainly by mutations in islet transcription factors (Murphy et al., 2008).”
BackgroundWeinreich, S. S., Bosma, A. R., Henneman, L., Rigter, T., Spruijt, C. M., Grimbergen, A., Breuning, M. H., de Koning, E. J. P., Losekoot, M., & Cornel, M. C. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.59 · Cited by 31
Dallali, H., Pezzilli, S., Hechmi, M., Sallem, O. K., Elouej, S., Jmel, H., Halima, Y. B., Chargui, M., Gharbi, M., Mercuri, L., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-018-01283-5 · Cited by 29
Myngheer, N., Allegaert, K., Hattersley, A., McDonald, T., Kramer, H., Ashcroft, F. M., Verhaeghe, J., Mathieu, C., & Casteels, K. (2014) · Diabetes Care · doi:10.2337/dc14-1247 · Cited by 24
Self-citationThe Genetic Architecture of Diabetes in Pregnancy: Implications for Clinical Practice
Kleinberger, J. W., Maloney, K. A., & Pollin, T. I. (2016) · American Journal of Perinatology · doi:10.1055/s-0036-1592078 · Cited by 26
Genetics of Type 2 Diabetes: Opportunities for Precision Medicine
Kim, D. S., Gloyn, A. L., & Knowles, J. W. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.346 · Cited by 27
Genetic Counseling for Diabetes Mellitus
Stein, S. A., Maloney, K. A., & Pollin, T. I. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0039-5 · Cited by 25
“HNF1A HNF1A-MODY (MODY3) T1DM Low-dose sulfonylureas instead of insulin Progressive, high complication risk Autosomal dominant [16]”
BackgroundInfluentialEvliyaoğlu, O., Ercan, O., Ataloğlu, E., Zübarioğlu, Ü., Özcabı, B., Çakır, A. D., Erdoğan, H. Ç., Franco, E. D., & Ellard, S. (2017) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.5162 · Cited by 28
“2), ABCC8 sulphonylurea receptor 1 (SUR1) and INS (insulin) compromise insulin secretion by affecting the mechanisms involved in insulin secretion (10,11,12,13,14).”
BackgroundSelf-citationThe prevalence of monogenic diabetes in Australia: the Fremantle Diabetes Study Phase II
Davis, T. M. E., Makepeace, A., Ellard, S., Colclough, K., Peters, K. E., Hattersley, A. T., & Davis, W. A. (2017) · The Medical Journal of Australia · doi:10.5694/mja16.01201 · Cited by 27
Self-citationLocke, J. M., Saint‐Martin, C., Laver, T. W., Patel, K., Wood, A. R., Sharp, S. A., Ellard, S., Bellanné‐Chantelot, C., Hattersley, A. T., Harries, L. W., et al. (2018) · Diabetes · doi:10.2337/db18-0133 · Cited by 27
“Although classically described as being an early-onset form of inherited diabetes (2), the age at which diabetes develops is highly variable, with individuals reported to develop diabetes across eight decades of life (4–74 years) (3).”
BackgroundSelf-citationAhamed, A., Unnikrishnan, A., Pendsey, S., Nampoothiri, S., Bhavani, N., Praveen, V. P., Kumar, H., Jayakumar, R. V., Nair, V., Ellard, S., et al. (2008) · PubMed · Cited by 25
Self-citationApproach to the patient with atypical diabetes
Steenkamp, D., Alexanian, S. M., & Sternthal, E. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.130185 · Cited by 22
Molecular background and clinical characteristics of HNF1A MODY in a Polish population
SKUPIEN, J. K., Górczyńska-Kosiorz, S. B., Klupa, T., Cyganek, K., Wanic, K., Borowiec, M., Sieradzki, J., & Malecki, M. T. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.05.004 · Cited by 23
“[1] Murphy R, Ellard S, Hattersley AT.”
BackgroundBacon, S., Kyithar, M. P., Condron, E. M., Vizzard, N., Burke, M., & Byrne, M. M. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0890-9 · Cited by 23
Agrawal, A., Narayan, G., Gogoi, R., & Thummer, R. P. (2021) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_653 · Cited by 24
Poitou, C., François, H., Bellanné‐Chantelot, C., Noël, C., Jacquet, A., Clauin, S., Beaudreuil, S., Damieri, H., Hebibi, H., HAMMOUDI, Y., et al. (2012) · Transplant International · doi:10.1111/j.1432-2277.2012.01458.x · Cited by 22
“MODY usually occurs before the age of 25 in non-obese children or young adults, and accounts for 1 to 2% of all cases of diabetes in industrialized countries [1].”
BackgroundMonogenic diabetes and pregnancy
Murphy, R. (2015) · Obstetric Medicine · doi:10.1177/1753495x15590713 · Cited by 22
“Monogenic beta-cell diabetes is thought to be responsible for approximately 2% of all diabetes cases diagnosed before the age of 45 years.(4) Approximately 80% of cases are misdiagnosed as either type 1 or type 2 diabetes, reflecting lack of physician awareness and / or access to genetic testing.”
BackgroundSelf-citationMezghani, N., Mnif, M. F., Mkaouar‐Rebai, E., Kallel, N., Charfi, N., Abid, M., & Fakhfakh, F. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.063 · Cited by 21
Molecular diagnosis of maturity onset diabetes of the young in India
Nair, V. V., Chapla, A., Arulappan, N., & Thomas, N. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.111636 · Cited by 24
“[78‐80] It is therefore important to characterize the different types of MODY and to distinguish it from other types of diabetes, because the treatment protocols for achieving optimal glycaemic control are specific for each type of MODY.”
BackgroundWhen is it MODY? Challenges in the Interpretation of Sequence Variants in MODY Genes
Althari, S., & Gloyn, A. L. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.330 · Cited by 28
“Genetically discriminating MODY from other types of diabetes, as well as MODY subtypes from each other, is of vital importance, as each is associated with a discrete etiology and a unique set of complications with different implications for treatment and management [8, 41, 42].”
BackgroundInfluentialFantasia, K. L., & Steenkamp, D. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00278 · Cited by 23
“Along with mutations in the glucokinase gene, mutations in the hepatocyte nuclear factor 1⍺ (HNF1A) gene account for most cases [1].”
BackgroundИванощук, Д. Е., Шахтшнейдер, Е. В., Rymar, O. D., Ovsyannikova, A. K., Михайлова, С. В., Orlov, P. S., Ragino, Y. I., & Voevoda, M. I. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030100 · Cited by 20
“MODY differs from the main diabetes types—type 1 diabetes mellitus (T1DM) and T2DM—in the clinical course, treatment strategies, and prognosis [1].”
BackgroundGloyn, A. L., Faber, J. H., Malmodin, D., Thanabalasingham, G., Lam, F., Ueland, P. M., McCarthy, M. I., Owen, K. R., & Baunsgaard, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040962 · Cited by 25
“There are significant clinical implications for both patients and their relatives associated with finding a genetic aetiology underlying their diabetes and it is therefore important to identify these individuals [3,4].”
BackgroundEdghill, E. L., Minton, J. A. L., Groves, C. J., Flanagan, S. E., Patch, A., Rubio‐Cabezas, O., Shepherd, M. H., Lenzen, S., McCarthy, M. I., Ellard, S., et al. (2016) · PubMed · doi:10.6092/1590-8577/3864 · Cited by 20
“To date there are ten genetic subtypes for PNDM; KCNJ11, ABCC8, INS, GCK, IPF1, FOXP3, EIF2AK3, PTF1A, SLC19A2 and GLIS3 [2].”
BackgroundInfluentialSelf-citationMishra, A. K., Pandey, M., Pannu, A. S., Dewangan, H. K., & Sahoo, P. K. (2023) · Current Traditional Medicine · doi:10.2174/2215083810666230501212125 · Cited by 30
Pathogenesis of the Metabolic Syndrome: Insights from Monogenic Disorders
Murphy, R., Carroll, R. W., & Krebs, J. D. (2013) · Mediators of Inflammation · doi:10.1155/2013/920214 · Cited by 25
Self-citationClinical application of ACMG‐AMP guidelines in HNF1A and GCK variants in a cohort of MODY families
de Santana, L. S., Caetano, L. A., Costa‐Riquetto, A. D., Quedas, E. P. S., Nery, M., Collett‐Solberg, P. F., Boguszewski, M. C. D. S., Vendramini, M. F., Crisostomo, L. G., Floh, F. O., et al. (2017) · Clinical Genetics · doi:10.1111/cge.12988 · Cited by 28
“Genetic analysis is required to confirm the diagnosis and is important for clinical management as the genetic subtype defines the treatment and follow up.(19) Proper clinical correlation between a genetic variant and its probably phenotype is a crucial step for any molecular genetic testing.”
BackgroundResultHu, M., Cherkaoui, I., Misra, S., & Rutter, G. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.576632 · Cited by 27
“GCK Enzyme in the first step of glucose metabolism Progressive b cell dysfunction Hyperglycaemia Reduced insulin secretion Reduced hepatic glycogen synthesis and stores (11) HNF1A Transcription factor Progressive b cell dysfunction Reduced b cell proliferation and increased apoptosis Glycosuria, sensitivity to sulphon…”
BackgroundInfluentialИванощук, Д. Е., Шахтшнейдер, Е. В., Rymar, O. D., Ovsyannikova, A. K., Михайлова, С. В., Fishman, V., Valeev, E., Orlov, P. S., & Voevoda, M. I. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11010057 · Cited by 24
“This type of diabetes (OMIM # 606391) differs from classic types of diabetes mellitus (types 1 and 2, or T1DM and T2DM) in its clinical course, treatment strategies, and prognosis [1,2].”
BackgroundTo test, or not to test: time for a MODY calculator?
Njølstad, P. R., & Molven, A. (2012) · Diabetologia · doi:10.1007/s00125-012-2514-4 · Cited by 20
“Thus, some authors have argued that the term MODY should be considered obsolete and substituted by ‘monogenic diabetes’ [3].”
BackgroundBurgos, J. I., Vallier, L., & Rodríguez‐Seguí, S. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.692596 · Cited by 18
“Over 30 subtypes of monogenic diabetes have been identified to date, each having a characteristic phenotype and a specific pattern of inheritance (6, 7).”
BackgroundGLIS3: A Critical Transcription Factor in Islet β-Cell Generation
Scoville, D. W., & Jetten, A. M. (2021) · Cells · doi:10.3390/cells10123471 · Cited by 21
“With the exception of monogenic diabetes, where β-cell or pancreatic dysfunction is linked to mutations in one particular gene [3], diabetes mostly results from a combination of genetic and environmental factors.”
Backgroundvan der Zwaag, A. M., Weinreich, S. S., Bosma, A. R., Rigter, T., Losekoot, M., Henneman, L., & Cornel, M. C. (2014) · Public Health Genomics · doi:10.1159/000367963 · Cited by 20
Familial young‐onset forms of diabetes related to HNF4A and rare HNF1A molecular aetiologies
Carette, C., Dubois‐Laforgue, D., Saint‐Martin, C., Clauin, S., Beaufils, S., Larger, É., Sola‐Gazagnes, A., Mosnier-Pudar, H., Timsit, J., & Bellanné‐Chantelot, C. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03115.x · Cited by 22
Role of Actionable Genes in Pursuing a True Approach of Precision Medicine in Monogenic Diabetes
Marucci, A., Rutigliano, I., Fini, G., Pezzilli, S., Menzaghi, C., Paola, R. D., & Trischitta, V. (2022) · Genes · doi:10.3390/genes13010117 · Cited by 25
Treatment of Transient Neonatal Diabetes Mellitus: Insulin Pump or Insulin Glargine? Our Experience
Passanisi, S., Timpanaro, T., Presti, D. L., Mammì, C., & Caruso‐Nicoletti, M. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0055 · Cited by 18
“There are two forms of NDM: transient (TNDM) and permanent (PNDM), which are characterized by different pathogenesis and clinical evolution.(1,4) The genetic causes of NDM have been identified in 90% of TNDM and 70% of PNDM cases.”
BackgroundZhang, X., Qiao, H., Zhao, Y., Wang, X., Sun, H., Liu, A., Xu, L., Sun, D., Jin, Y., Yu, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052938 · Cited by 18
“Both are expressed in the pancreas, liver, and kidney [8,9].”
BackgroundClinicopathologic Characterization of Naturally Occurring Diabetes Mellitus in Vervet Monkeys
Cann, J. A., Kavanagh, K., Jorgensen, M. J., Mohanan, S., Howard, T. D., Gray, S. B., Hawkins, G. A., Fairbanks, L. A., & Wagner, J. D. (2010) · Veterinary Pathology · doi:10.1177/0300985810370011 · Cited by 19
“Even so, the phenotypic expression of these related conditions is quite diverse, and authors have suggested that the term MODY as a clinical diagnosis be replaced with a more suitable description based on genetic subgroup.(10) These subgroups consist of neonatal DM, mild hyperglycemia caused by mutations in GCK, DM as…”
Background‘Omics’‐driven discoveries in prevention and treatment of type 2 diabetes
Gjesing, A. P., & Pedersen, O. B. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2012.02678.x · Cited by 19
A Clinical Guide to Monogenic Diabetes
Carmody, D., Støy, J., Greeley, S. A. W., Bell, G. I., & Philipson, L. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800892-8.00002-6 · Cited by 25
CONN, J. J., Simm, P. J., Oats, J. J. N., Nankervis, A. J., Jacobs, S. E., Ellard, S., & Hattersley, A. T. (2009) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2009.01009.x · Cited by 18
Self-citationDiagnosis and Treatment of MODY: An Updated Mini Review
Tshivhase, A. M., Matsha, T. E., & Raghubeer, S. (2021) · Applied Sciences · doi:10.3390/app11209436 · Cited by 22
“Furthermore, 63% of patients develop diabetes before the age of 25, 79% before the age of 35, and 96% before the age of 55 [34,37].”
BackgroundGenetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics
Glamočlija, U., & Čaušević, A. (2010) · Acta Pharmaceutica · doi:10.2478/v10007-010-0040-9 · Cited by 17
“Diabetes diagnosed before 6 months of age is likely to be one of the monogenic forms of neonatal diabetes (5).”
BackgroundMaraschin, J. D. F., Kannengiesser, C., Murussi, N., Campagnolo, N., Canani, L. H. S., Gross, J. L., Velho, G., Grandchamp, B., & Silveiro, S. P. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000800020 · Cited by 16
Structural Lessons From the Mutant Proinsulin Syndrome
Dhayalan, B., Chatterjee, D., Chen, Y., & Weiss, M. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.754693 · Cited by 22
Metadata
- Authors
- Murphy, R., Ellard, S., & Hattersley, A. T.
- Affiliations
- University of Exeter (GB)
- Corresponding author
- Hattersley, Andrew T
- Venue
- Nature Clinical Practice Endocrinology & Metabolism
- Published
- 2008-02-26
- Volume
- 4
- Issue
- 4
- Pages
- 200-213
- ISSN
- 1745-8366 (ISSN-L)
- 1745-8374
- OpenAlex
- W1996549380
- Semantic Scholar
- ca1487d43edc4a5abbe40904a2e6414a4534638e
- Cited by
- 502
- References
- 91
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 10 · 2023: 18 · 2022: 17 · 2021: 33 · 2020: 23 · 2019: 21 · 2018: 34 · 2017: 32 · 2016: 33 · 2015: 33 · 2014: 36 · 2013: 29 · 2012: 42
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Clinical Practice Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- monogenic diabetes, maturity-onset diabetes of the young, neonatal diabetes, molecular genetic classification, Kir6.2, SUR1, sulfonylurea therapy, glucokinase mutations, HNF1A, HNF4α, HNF1B, genetic counseling, insulin therapy
- MeSH terms
- Kcnj11 Channel, Diabetes Mellitus, Diagnosis, Differential, Female, Glucokinase, Humans, Infant, Newborn, Male, Mutation, Receptors, Drug, Potassium Channels, ATP-Binding Cassette Transporters, Potassium Channels, Inwardly Rectifying, Insulin-Secreting Cells, Hepatocyte Nuclear Factor 1-alpha, Hepatocyte Nuclear Factor 4, Sulfonylurea Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.